The Investor Relations website contains information about Cyclacel Pharmaceuticals, Inc.'s business for stockholders, potential investors, and financial analysts.
http://investor.cyclacel.com/
TODAY'S RATING
>1,000,000
Date Range
HIGHEST TRAFFIC ON
Friday
LOAD TIME
0.3 seconds
16x16
32x32
64x64
128x128
PAGES IN
THIS WEBSITE
17
SSL
EXTERNAL LINKS
55
SITE IP
23.55.218.214
LOAD TIME
0.31 sec
SCORE
6.2
Overview | Cyclacel Pharmaceuticals, Inc. | investor.cyclacel.com Reviews
https://investor.cyclacel.com
The Investor Relations website contains information about Cyclacel Pharmaceuticals, Inc.'s business for stockholders, potential investors, and financial analysts.
investor.cyclacel.com
Investors & Media: Shareholder Briefcase Registration
http://investor.cyclacel.com/briefcase.cfm
Research and Development Pipeline. CYC116 Aurora Kinase and VEGFR2 Inhibitor. Cell Cycle in Cancer. Drug Discovery and Development Approach. Corporate Presentations and Events. Collect, zip and download files from our Investor Relations website. Click on the briefcase icon. Located near most downloadable files throughout our IR website and use this page to manage your briefcase. Please fill in the form below to access this feature. *. Fixed Income Analyst (sell-side). Fixed Income Analyst (buy-side).
Investors & Media: Analysts
http://investor.cyclacel.com/analysts.cfm
Research and Development Pipeline. CYC116 Aurora Kinase and VEGFR2 Inhibitor. Cell Cycle in Cancer. Drug Discovery and Development Approach. Corporate Presentations and Events. Michael G. King, Jr. Phone: 212 906 3520. Laidlaw and Company Ltd. Issued by the Board of Directors and Management of Cyclacel ("The Company"). Corporate Presentations and Events. Website created by Princeton Internet Group (PING).
Investors & Media: News
http://investor.cyclacel.com/releases.cfm
Research and Development Pipeline. CYC116 Aurora Kinase and VEGFR2 Inhibitor. Cell Cycle in Cancer. Drug Discovery and Development Approach. Corporate Presentations and Events. Cyclacel Pharmaceuticals Reports 2nd Quarter 2016 Financial Results. Aug 10, 2016. Cyclacel Pharmaceuticals to Release Second Quarter 2016 Financial Results. Aug 3, 2016. Cyclacel's CYC065 Demonstrates Promising Activity in Uterine Serous Carcinoma in Preclinical Data Published by Independent Academic Researchers. Aug 2, 2016.
Investors & Media: Common Stock Information
http://investor.cyclacel.com/stockquote.cfm
Research and Development Pipeline. CYC116 Aurora Kinase and VEGFR2 Inhibitor. Cell Cycle in Cancer. Drug Discovery and Development Approach. Corporate Presentations and Events. Cyclacel Pharmaceuticals (NASDAQ: CYCC). 4:00 PM ET on Aug 22, 2016. Sign up for email alerts. Corporate Presentations and Events. Website created by Princeton Internet Group (PING).
Investors & Media: SEC Filings
http://investor.cyclacel.com/sec.cfm
Research and Development Pipeline. CYC116 Aurora Kinase and VEGFR2 Inhibitor. Cell Cycle in Cancer. Drug Discovery and Development Approach. Corporate Presentations and Events. Statement of beneficial ownership. Aug 19, 2016. Aug 11, 2016. Aug 10, 2016. Jul 6, 2016. Prospectus filed pursuant to rule 424. Jun 24, 2016. Jun 23, 2016. Prospectus filed pursuant to rule 424. Jun 10, 2016. Jun 3, 2016. Uprichard, david c. May 31, 2016. May 31, 2016. Hradsky, gregory t. May 31, 2016. Henney, christopher s.
TOTAL PAGES IN THIS WEBSITE
17
Committee structure and membership composition of Cyclacel
http://www.cyclacel.com/investors_corpgov.shtml
Research and Development Pipeline. Cell Cycle in Cancer. Drug Discovery and Development Approach. Corporate Presentations and Events. Cyclacel is committed to maintaining high ethical standards in its business operations. The following documents describe these standards and the internal policies we have established to communicate and monitor them. Amended and Restated Charter for the Audit Committee of the Board of Directors. Nominating And Corporate Governance Committee Charter.
Overview of the company and its pharmaceutical efforts to control cancer and other serious diseases | Cyclacel
http://www.cyclacel.com/about.shtml
Research and Development Pipeline. Cell Cycle in Cancer. Drug Discovery and Development Approach. Corporate Presentations and Events. Cyclacel's most advanced product candidate, is the subject of SEAMLESS, a Phase 3 trial, which has completed enrollment and is being conducted under an SPA with the FDA as front-line treatment for acute myeloid leukemia (AML) in the elderly, and other indications including myelodysplastic syndromes (MDS). Cyclacel's pipeline includes an oral regimen of seliciclib. Cyclacel...
Committee structure and membership composition of Cyclacel
http://www.cyclacel.com/investors_corpgov_committee.shtml
Research and Development Pipeline. Cell Cycle in Cancer. Drug Discovery and Development Approach. Corporate Presentations and Events. Below is a summary of our committee structure and membership information. To read more about any of the committee members click on the names in the chart below. Samuel L. Barker, Ph.D. Christopher Henney, Ph.D. David UPrichard, Ph.D. Corporate Presentations and Events. Website created by Princeton Internet Group (PING).
Cyclacel SiteMap - A directory of pages on the Cyclacel Website
http://www.cyclacel.com/sitemap.shtml
Research and Development Pipeline. Cell Cycle in Cancer. Drug Discovery and Development Approach. Corporate Presentations and Events. Research and Development Pipeline. Cell Cycle in Cancer. Corporate Presentations and Events. Research and Development Pipeline. Website created by Princeton Internet Group (PING).
Professor Kenneth Harrap, Professor Stanley Kaye, Professor Michel Marty, Professor Enrico Mihich, Professor Karol Sikora | Cyclacel Scientific Advisory Board
http://www.cyclacel.com/about_scientific-advisory-board.shtml
Research and Development Pipeline. Cell Cycle in Cancer. Drug Discovery and Development Approach. Corporate Presentations and Events. Professor Kenneth Harrap, CBE, Ph.D., DSc, F.R.S.C. Professor Stanley Kaye, M.D. F.R.C.P. CRC Professor of Medical Oncology, Institute of Cancer Research, The Royal Marsden Hospital. Former Head of Department, CRC Department of Medical Oncology, University of Glasgow and CRC Professor of Medical Oncology, University of Glasgow, since 1981. Professor Kaye is a renow...His p...
Binding conditions for using the Website | Cyclacel Pharmaceuticals, Inc.
http://www.cyclacel.com/disclaimer.shtml
Research and Development Pipeline. Cell Cycle in Cancer. Drug Discovery and Development Approach. Corporate Presentations and Events. The pages on the Website (the Website) are published by Cyclacel Pharmaceuticals, Inc. The information contained on the Website is not an invitation to invest in the shares, or any other products or services or otherwise deal in these or enter into a contract with Cyclacel Pharmaceuticals or any other company. The information provided should not be relied upon in conne...
Alliances and collaborations with the biopharmaceutical company developing cell cycle control cancer therapies | Cyclacel
http://www.cyclacel.com/about_alliances.shtml
Research and Development Pipeline. Cell Cycle in Cancer. Drug Discovery and Development Approach. Corporate Presentations and Events. Cyclacel Pharmaceuticals remains interested in the following alliance frameworks:. Where appropriate, Cyclacel Pharmaceuticals seeks early stage partners with unique program specific requisite expertise. Such representative programs may encompass Inflammatory Kidney Disease and Diabetes. Research and Development Pipeline. Website created by Princeton Internet Group (PING).
Spiro Rombotis, Paul McBarron, Professor David Glover, Judy Chiao, Susan Davis, Robert Sosnowski | Cyclacel Management Team
http://www.cyclacel.com/about_management-team.shtml
Research and Development Pipeline. Cell Cycle in Cancer. Drug Discovery and Development Approach. Corporate Presentations and Events. President and Chief Executive Officer. Executive Vice President, Finance and Chief Operating Officer and Secretary. Professor David Glover, Ph.D. FRS FRSE. Judy Chiao, M.D. Vice President, Clinical Development and Regulatory Affairs. Susan Davis, Ph.D. Director, Business Development. Research and Development Pipeline. Website created by Princeton Internet Group (PING).
Career opportunities at Cyclacel
http://www.cyclacel.com/careers.shtml
Research and Development Pipeline. Cell Cycle in Cancer. Drug Discovery and Development Approach. Corporate Presentations and Events. Welcome to Cyclacel Pharmaceuticals' employment site and thank you for considering us as a potential employer. The Cyclacel Pharmaceuticals team is dedicated to meeting the company's goal - to develop novel, cell-cycle based therapies for the treatment of cancer to enhance the quality of life and improve survival rates of cancer patients. Tel: 44 1382 206 062.
TOTAL LINKS TO THIS WEBSITE
55
ctnet.com - This website is for sale! - ctnet Resources and Information.
The domain ctnet.com. May be for sale by its owner! This webpage was generated by the domain owner using Sedo Domain Parking. Disclaimer: Sedo maintains no relationship with third party advertisers. Reference to any specific service or trade mark is not controlled by Sedo nor does it constitute or imply its association, endorsement or recommendation.
Cummins.com > Disclaimer
Online Parts and Service. Annual Meeting / Proxy Materials. Disclosure Regarding Forward-Looking Statements:. I have read this disclaimer. 2014 Cummins Inc.,Box 3005, Columbus, IN 47202-3005 U.S.A.
皇將科技 - 投資人資訊
版權所有 皇將科技股份有限公司 ADD:台中市大里區工業九路190號 TEL: 886 4 3705-6666 FAX: 886 4 3705-6555.
Overview | Cyalume
Covering the EMEA Region. Where To Find Us. We are committed to serving the best interests of our shareholders. You will find key shareholder information and financial reports available to help put Cyalumes financial performance into perspective. 2:26 PM ET on Sep 19, 2017. Delayed at least 20 minutes. Annual Reports and Proxies. Aug 8, 2017. Cyalume Technologies Holdings, Inc. to Be Acquired by an Affiliate of Arsenal Capital Partners. Cyalume Technologies, Inc. 910 SE 17th Street. 33 (0) 4 42 37 17 80.
Q4 Web Site Development
Q4 Web Maintenance Message. This site is currently under development and not yet available for public viewing. For more information on why this site is not available, please contact Q4.
Overview | Cyclacel Pharmaceuticals, Inc.
Skip to main navigation. Research and Development Pipeline. CYC116 Aurora Kinase and VEGFR2 Inhibitor. Cell Cycle in Cancer. Drug Discovery and Development Approach. Corporate Presentations and Events. We are committed to serving the best interests of our shareholders. You will find key shareholder information and financial reports available to help put Cyclacel Pharmaceuticals, Inc.'s financial performance into perspective. Fourth Quarter and Full Year 2017 Financial Results. 30th Annual ROTH Conference.
China Yuchai International Limited (“CYI”) - Investor Relations - Investors Home
Q2 2015 China Yuchai International Limited Earnings Conference Call. 160;at 8:00 pm ET. Q2 2015 China Yuchai International Limited Earnings Conference Call. Tuesday, August 11, 2015 . 8:00 pm ET . Through Tuesday, August 11, 2015 . Click here for webcast. Click here to add this event to your calendar. CYI has also invested in HL Global Enterprises Limited ( HLGE ) which is listed on the main board of the Singapore Exchange. Currently, CYI holds 48.9% shareholding interest in HLGE. The core businesses of...
Cyxone » Investor relations
Cyxone är ett resurssnålt bolag. Cyxone är ett resurssnålt bolag fokuserat på att utveckla läkemedelskandidaten T20K mot Multipel Skleros (MS). T20K har passerat forskningsstadiet vilket kortar ner tiden till värdehöjande händelser som t.ex. kliniska studier. De egenskaper T20K visat i cell- och djurstudier har potential att utveckla substansen till en genombrottsprodukt för att behandla MS-patienter i olika sjukdomsstadier. VD Kjell Stenberg presenterar Cyxone på Stora Aktiedagen i Stockholm.
WEST BROKERS a.s.
Vážení zákazníci, dovolujeme si Vás seznámit se změnami, ke kterým došlo u obchodníka s cennými papíry WEST BROKERS a.s., IČ: 64832341, se sídlem Slovanská 100, 326 00 Plzeň, zapsaný v OR vedeném Krajským soudem v Plzni, oddíl B, vložka 1004. V souladu s ustanovením 18 odst. 2, zákona č. 256/2004 Sb., o podnikání na kapitálovém trhu společnost WEST BROKERS a.s. od účinnosti rozhodnutí valné hromady, tj. od 31.5.2008 pouze vydává zákaznický majetek a vypořádává své pohledáv...
Daily Investors
Annualised revenue per service per customer starts. At 259 for domain registration services up to 350k for. A PCI DSS Hosting cluster (‘Payment Card Industry Data. Now provides a broad range of infrastructure and cloud based services. To individuals, small to medium enterprises ( SMEs ) and larger corporates. To become the one-stop supplier of reliable, scalable, high performance. And resilient infrastructure based hosting products. OUR BUSINESS STATISTICS and INFORMATION.
Investor Relations | Daktronics, Inc.
Skip to main navigation. Out of Home Advertising. Digit and Price Displays. ITS Dynamic Message Signs. Annual Reports and Proxy. Annual Reports and Proxy. News and Event Alerts. Daktronics designs, manufactures, sells and services dynamic visual communication systems for customers worldwide. Daktronics is a public corporation whose stock is traded on the Nasdaq national market under the symbol DAKT. Mar 28, 2018. Daktronics Unveils Major Innovation For Traffic Applications. Mar 27, 2018. Mar 02, 2018.
SOCIAL ENGAGEMENT